

MD7510 Clinical Presentation & Management in Diabetes: Glycaemic Control, New & Novel Therapies (DL)

View Online



1.

Diagnosis and management of type 1 diabetes in children, young people and adults | Guidance and guidelines | NICE. NICE; Available from: <https://www.nice.org.uk/guidance/cg15>

2.

Type 2 diabetes in adults: management | Guidance and guidelines | NICE. NICE; Available from: <https://www.nice.org.uk/guidance/ng28>

3.

Efficacy and Safety of Glucagon-like peptide-1 receptor agonists in type 2 diabetes Systematic review and mixed-treatment comparison analysis. Available from: <http://onlinelibrary.wiley.com.ezproxy3.lib.le.ac.uk/doi/10.1111/dom.12849/epdf>

4.

Obesity: identification, assessment and management | Guidance and guidelines | NICE. NICE; Available from: <https://www.nice.org.uk/guidance/cg189>

5.

Managing Older People with Type 2 Diabetes: IDF Global Guideline - International Federation on Ageing [Internet]. Available from: <https://www.ifa-fiv.org/managing-older-people-with-type-2-diabetes-idf-global-guideline/>

6.

NHS Evidence: an introduction [Internet]. Available from:
http://www.solent.nhs.uk/_store/documents/nhs_evidence_guide.pdf

7.

Holt RIG, Cockram C, Flyvbjerg A, Goldstein BJ. Textbook of Diabetes [Internet]. 5th ed. Somerset: John Wiley & Sons, Incorporated; 2016. Available from:
<http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056>

8.

Holt RIG. Textbook of diabetes [Internet]. 4th ed. Chichester: Wiley-Blackwell; 2010. Available from: <http://ezproxy.lib.le.ac.uk/login?url=http://www.mylibrary.com?id=269077>

9.

Atkinson MA. The Pathogenesis and Natural History of Type 1 Diabetes. Cold Spring Harbor Perspectives in Medicine. 2012 Nov 1;2(11):a007641–a007641.

10.

Jelinek HF, Stranieri A, Yatsko A, Venkatraman S. Data analytics identify glycated haemoglobin co-markers for type 2 diabetes mellitus diagnosis. Computers in Biology and Medicine. 2016 Aug;75:90–97.

11.

S M Attard. Implications of iron deficiency/anemia on the classification of diabetes using HbA1c. Nutrition & Diabetes [Internet]. Nature Publishing Group; 2015;5(6). Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4491857/>

12.

Samuel VT, Shulman GI. Intergrating Mechanisms for Insulin Resistance: Common Threads and Missing Links. Cell. 2012 Mar;148(5):852–871.

13.

Beverley M Shields. Can clinical features be used to differentiate type 1 from type 2 diabetes? A systematic review of the literature. *BMJ Open* [Internet]. BMJ Group; 2015;5(11). Available from:
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4636628/?report=classic>

14.

Zaccardi F, Webb DR, Yates T, Davies MJ. Pathophysiology of type 1 and type 2 diabetes mellitus: a 90-year perspective. *Postgraduate Medical Journal*. 2016 Feb;92(1084):63–69.

15.

Anthony H. Barnett, Jenny Grice. *New Mechanisms in Glucose Control* [Internet]. BMJ Books; 1 edition; 2013. Available from:
<http://ezproxy.lib.le.ac.uk/login?url=http://lib.myilibrary.com?id=478133>

16.

Gregg EW. The Changing Tides of the Type 2 Diabetes Epidemic—Smooth Sailing or Troubled Waters Ahead? Kelly West Award Lecture 2016. *Diabetes Care*. 2017 Aug 10;

17.

Holt RIG, Cockram C, Flyvbjerg A, Goldstein BJ. *Textbook of Diabetes* [Internet]. 5th ed. Somerset: John Wiley & Sons, Incorporated; 2016. Available from:
<http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056>

18.

Holt RIG. *Textbook of diabetes* [Internet]. 4th ed. Chichester: Wiley-Blackwell; 2010. Available from: <http://ezproxy.lib.le.ac.uk/login?url=http://www.myilibrary.com?id=269077>

19.

Copeland KC, Silverstein J, Moore KR, Prazar GE, Raymer T, Shiffman RN, Springer SC, Thaker VV, Anderson M, Spann SJ, Flinn SK. Management of Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) in Children and Adolescents. *PEDIATRICS*. 2013 Feb 1;131(2):364-382.

20.

Kenneth Hodson. Gestational diabetes: emerging concepts in pathophysiology. *Obstetric Medicine* [Internet]. SAGE Publications; 2010;3(4). Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4989628/?report=classic>

21.

Latika Sahu. Comparison of the American Diabetes Association and World Health Organization criteria for gestational diabetes mellitus and the outcomes of pregnancy. *Obstetric Medicine* [Internet]. SAGE Publications; 2009;2(4). Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4989660/?report=classic>

22.

Schwartz SS, Epstein S, Corkey BE, Grant SFA, Gavin JR, Aguilar RB. The Time Is Right for a New Classification System for Diabetes: Rationale and Implications of the β -Cell-Centric Classification Schema. *Diabetes Care*. 2016 Feb;39(2):179-186.

23.

Nolan CJ, Ruderman NB, Kahn SE, Pedersen O, Prentki M. Insulin Resistance as a Physiological Defense Against Metabolic Stress: Implications for the Management of Subsets of Type 2 Diabetes. *Diabetes*. 2015 Mar;64(3):673-686.

24.

Gale EA. Is type 2 diabetes a category error? *The Lancet*. 2013 Jun;381(9881):1956-1957.

25.

Moreno-Castilla C, Mauricio D, Hernandez M. Role of Medical Nutrition Therapy in the Management of Gestational Diabetes Mellitus. *Current Diabetes Reports*. 2016 Apr;16(4).

26.

Noctor E, Dunne F. Postnatal testing following gestational diabetes. *The Lancet Diabetes & Endocrinology*. 2015 Oct;3(10):761–762.

27.

Birkeland KI. Hyperglycaemia in pregnancy: still a lot to learn. *The Lancet Diabetes & Endocrinology*. 2015 Oct;3(10):752–753.

28.

Rinki Murphy. Monogenic diabetes and pregnancy. *Obstetric Medicine [Internet]*. SAGE Publications; 2015;8(3). Available from:
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4935018/>

29.

Stewart ZA, Wilinska ME, Hartnell S, Temple RC, Rayman G, Stanley KP, Simmons D, Law GR, Scott EM, Hovorka R, Murphy HR. Closed-Loop Insulin Delivery during Pregnancy in Women with Type 1 Diabetes. *New England Journal of Medicine*. 2016 Aug 18;375(7):644–654.

30.

Diabetes in pregnancy: management of diabetes and its complications from preconception to the postnatal period (NG3 [Internet]). Available from:
<https://www.nice.org.uk/guidance/ng3>

31.

Jones AG, Hattersley AT. The clinical utility of C-peptide measurement in the care of patients with diabetes. *Diabetic Medicine*. 2013 Jul;30(7):803–817.

32.

Unit 3 – Special care groups: A practical guide to pregnancy complicated by diabetes - Diabetes & Primary Care [Internet]. Available from:
<http://www.diabetesandprimarycare.co.uk/journal-content/view/unit-3-special-care-groups-a-practical-guide-to-pregnancy-complicated-by-diabetes/?preview>

33.

Brown J, Alwan NA, West J, Brown S, McKinlay CJ, Farrar D, Crowther CA. Lifestyle interventions for the treatment of women with gestational diabetes. Cochrane Database of Systematic Reviews [Internet]. Chichester, UK: John Wiley & Sons, Ltd; 1996. Available from: <http://doi.wiley.com/10.1002/14651858.CD011970.pub2>

34.

Rasouli B, Andersson T, Carlsson PO, Hjort R, Löfvenborg JE, Martinell M, Groop L, Tuomi T, Carlsson S. Serious life events and the risk of latent autoimmune diabetes in adults (LADA) and Type 2 diabetes. *Diabetic Medicine*. 2017 Sep;34(9):1259–1263.

35.

Davies M, Dahl D, Heise T, Kiljanski J, Mathieu C. Introduction of biosimilar insulins in Europe. *Diabetic Medicine*. 2017 Oct;34(10):1340–1353.

36.

Perrin NE, Davies MJ, Robertson N, Snoek FJ, Khunti K. The prevalence of diabetes-specific emotional distress in people with Type 2 diabetes: a systematic review and meta-analysis. *Diabetic Medicine*. 2017 Nov;34(11):1508–1520.

37.

Holt RIG, Cockram C, Flyvbjerg A, Goldstein BJ. *Textbook of Diabetes* [Internet]. 5th ed. Somerset: John Wiley & Sons, Incorporated; 2016. Available from:
<http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056>

38.

Holt RIG. *Textbook of diabetes* [Internet]. 4th ed. Chichester: Wiley-Blackwell; 2010. Available from: <http://ezproxy.lib.le.ac.uk/login?url=http://www.myilibrary.com?id=269077>

39.

Standards of Medical Care in Diabetes--2015: Summary of Revisions. *Diabetes Care*. 2015 Jan 1;38(Supplement_1):S4-S4.

40.

A Randomised trial of the effect and cost-effectiveness of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with screen-detected type 2 diabetes: the anglo-Danish-Dutch Study of intensive Treatment in People with Screen-Detected Diabetes in Primary care (ADDITION-Europe) study. Available from: <http://www.journalslibrary.nihr.ac.uk/hta/volume-20/issue-64#abstract>

41.

Kamlesh Khunti. Systematic Review and Meta-Analysis of Response Rates and Diagnostic Yield of Screening for Type 2 Diabetes and Those at High Risk of Diabetes. *PLoS ONE* [Internet]. Public Library of Science; 2015;10(9). Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4556656/?report=classic>

42.

Tao L, Wilson ECF, Wareham NJ, Sandbaek A, Rutten GEHM, Lauritzen T, Khunti K, Davies MJ, Borch-Johnsen K, Griffin SJ, Simmons RK. Cost-effectiveness of intensive multifactorial treatment compared with routine care for individuals with screen-detected Type 2 diabetes: analysis of the ADDITION-UK cluster-randomized controlled trial. *Diabetic Medicine*. 2015 Jul;32(7):907-919.

43.

Gray LJ, Khunti K, Wilmot EG, Yates T, Davies MJ. External validation of two diabetes risk scores in a young UK South Asian population. *Diabetes Research and Clinical Practice*. 2014 Jun;104(3):451-458.

44.

Gray LJ, Khunti K, Edwardson C, Goldby S, Henson J, Morris DH, Sheppard D, Webb D,

Williams S, Yates T, Davies MJ. Implementation of the automated Leicester Practice Risk Score in two diabetes prevention trials provides a high yield of people with abnormal glucose tolerance. *Diabetologia*. 2012 Dec;55(12):3238–3244.

45.

Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetes Care*. 2015 Jan;38(1):140–149.

46.

Guidelines [Internet]. Available from:
<https://www.idf.org/e-library/guidelines/79-global-guideline-for-type-2-diabetes>

47.

Holt RIG, Cockram C, Flyvbjerg A, Goldstein BJ. Textbook of Diabetes [Internet]. 5th ed. Somerset: John Wiley & Sons, Incorporated; 2016. Available from:
<http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056>

48.

Holt RIG. Textbook of diabetes [Internet]. 4th ed. Chichester: Wiley-Blackwell; 2010. Available from: <http://ezproxy.lib.le.ac.uk/login?url=http://www.myilibrary.com?id=269077>

49.

Holt RIG. Textbook of diabetes [Internet]. 4th ed. Chichester: Wiley-Blackwell; 2010. Available from: <http://ezproxy.lib.le.ac.uk/login?url=http://www.myilibrary.com?id=269077>

50.

Davies MJ, Heller S, Skinner TC, Campbell MJ, Carey ME, Craddock S, Dallosso HM, Daly H, Doherty Y, Eaton S, Fox C, Oliver L, Rantell K, Rayman G, Khunti K. Effectiveness of the

diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cluster randomised controlled trial. *BMJ*. 2008 Mar 1;336(7642):491-495.

51.

Johnston BC, Kanters S, Bandayrel K, Wu P, Naji F, Siemieniuk RA, Ball GDC, Busse JW, Thorlund K, Guyatt G, Jansen JP, Mills EJ. Comparison of Weight Loss Among Named Diet Programs in Overweight and Obese Adults. *JAMA*. 2014 Sep 3;312(9).

52.

Steven S, Hollingsworth KG, Al-Mrabeh A, Avery L, Aribisala B, Caslake M, Taylor R. Very Low-Calorie Diet and 6 Months of Weight Stability in Type 2 Diabetes: Pathophysiological Changes in Responders and Nonresponders. *Diabetes Care*. 2016 May;39(5):808-815.

53.

Steven S, Taylor R. Restoring normoglycaemia by use of a very low calorie diet in long- and short-duration Type 2 diabetes. *Diabetic Medicine*. 2015 Sep;32(9):1149-1155.

54.

Amy Kennedy. Does Exercise Improve Glycaemic Control in Type 1 Diabetes? A Systematic Review and Meta-Analysis. *PLoS ONE* [Internet]. Public Library of Science; 2013;8(3). Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3598953/>

55.

Chimen M, Kennedy A, Nirantharakumar K, Pang TT, Andrews R, Narendran P. What are the health benefits of physical activity in type 1 diabetes mellitus? A literature review. *Diabetologia*. 2012 Mar;55(3):542-551.

56.

Umpierre D. Physical Activity Advice Only or Structured Exercise Training and Association With HbA_{1c} Levels in Type 2 Diabetes. *JAMA*. 2011 May 4;305(17).

57.

Avery L, Flynn D, van Wersch A, Sniehotta FF, Trenell MI. Changing Physical Activity Behavior in Type 2 Diabetes: A systematic review and meta-analysis of behavioral interventions. *Diabetes Care*. 2012 Dec 1;35(12):2681–2689.

58.

Barry VW, Baruth M, Beets MW, Durstine JL, Liu J, Blair SN. Fitness vs. Fatness on All-Cause Mortality: A Meta-Analysis. *Progress in Cardiovascular Diseases*. 2014 Jan;56(4):382–390.

59.

Qin L, Knol MJ, Corpeleijn E, Stolk RP. Does physical activity modify the risk of obesity for type 2 diabetes: a review of epidemiological data. *European Journal of Epidemiology*. 2010 Jan;25(1):5–12.

60.

Lee IM. Physical Activity and Weight Gain Prevention. *JAMA*. 2010 Mar 24;303(12).

61.

John M Jakicic. Physical activity considerations for the treatment and prevention of obesity. *The American Journal of Clinical Nutrition* [Internet]. 2005 Jan 7;82(1):226S-229S. Available from: <http://ajcn.nutrition.org/content/82/1/226S>

62.

Heinonen I, Helajärvi H, Pahkala K, Heinonen OJ, Hirvensalo M, Pälve K, Tammelin T, Yang X, Juonala M, Mikkilä V, Kähönen M, Lehtimäki T, Viikari J, Raitakari OT. Sedentary behaviours and obesity in adults: the Cardiovascular Risk in Young Finns Study. *BMJ Open*. 2013 May;3(6).

63.

Sallis JF, Bull F, Guthold R, Heath GW, Inoue S, Kelly P, Oyeyemi AL, Perez LG, Richards J, Hallal PC. Progress in physical activity over the Olympic quadrennium. *The Lancet*. 2016

Sep;388(10051):1325-1336.

64.

Yeh JS, Kushner RF, Schiff GD. Obesity and Management of Weight Loss. *New England Journal of Medicine*. 2016 Sep 22;375(12):1187-1189.

65.

Henson, Joseph. Associations of Sedentary Time with Fat Distribution in a High-Risk Population. *American College of Sports Medicine (ACSM)*, Lippincott, Williams & Wilkins; 2014 Nov 10; Available from: <https://lra.le.ac.uk/handle/2381/32505>

66.

The Eatwell Guide [Internet]. Public Health England; 2016. Available from: <https://www.gov.uk/government/publications/the-eatwell-guide>

67.

Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus (review) TA151, July 2008 [Internet]. Available from: <http://www.nice.org.uk/guidance/ta151>

68.

Hadjiconstantinou M, Byrne J, Bodicoat DH, Robertson N, Eborall H, Khunti K, Davies MJ. Do Web-Based Interventions Improve Well-Being in Type 2 Diabetes? A Systematic Review and Meta-Analysis. *Journal of Medical Internet Research*. 2016 Oct 21;18(10).

69.

Young-Hyman D, de Groot M, Hill-Briggs F, Gonzalez JS, Hood K, Peyrot M. Erratum. Psychosocial Care for People With Diabetes: A Position Statement of the American Diabetes Association. *Diabetes Care* 2016;39:2126-2140. *Diabetes Care*. 2017 Feb;40(2):287.1-287.

70.

Capehorn M, Polonsky WH, Edelman S, Belton A, Down S, Gamerman V, Nagel F, Lee J, Alzaid A. Challenges faced by physicians when discussing the Type 2 diabetes diagnosis with patients: insights from a cross-national study (IntroDia). Diabetic Medicine. 2017 Mar;

71.

Hartman YAW, Jansen HJ, Hopman MTE, Tack CJ, Thijssen DHJ. Insulin-Associated Weight Gain in Type 2 Diabetes Is Associated With Increases in Sedentary Behavior. Diabetes Care. 2017 Sep;40(9):e120–e121.

72.

Hessler DM, Fisher L, Polonsky WH, Masharani U, Strycker LA, Peters AL, Blumer I, Bowyer V. Diabetes distress is linked with worsening diabetes management over time in adults with Type 1 diabetes. Diabetic Medicine. 2017 Sep;34(9):1228–1234.

73.

Ferrari M, Dal Cin M, Steele M. Self-compassion is associated with optimum self-care behaviour, medical outcomes and psychological well-being in a cross-sectional sample of adults with diabetes. Diabetic Medicine. 2017 Nov;34(11):1546–1553.

74.

William H. Polonsky, Lawrence Fisher, Jay Earles, R. James Dudl, Joel Lees, Joseph Mullan. Assessing psychosocial distress in diabetes: development of the Diabetes Distress Scale. Diabetes Care [Internet]. Available from:
http://go.galegroup.com.ezproxy3.lib.le.ac.uk/ps/retrieve.do?tabID=T002&resultListType=RESULT_LIST&searchResultsType=SingleTab&searchType=AdvancedSearchForm¤tPosition=25&docId=GALE%7CA130282980&docType=Article&sort=Relevance&contentSegment=&prodId=EAIM&contentSet=GALE%7CA130282980&searchId=R15&userGroupName=leicester&inPS=true

75.

Constructs of depression and distress in diabetes: time for an appraisal- ClinicalKey [Internet]. Available from:
<https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858715001357>

76.

Holt RIG, Cockram C, Flyvbjerg A, Goldstein BJ. Textbook of Diabetes [Internet]. 5th ed. Somerset: John Wiley & Sons, Incorporated; 2016. Available from: <http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056>

77.

Holt RIG. Textbook of diabetes [Internet]. 4th ed. Chichester: Wiley-Blackwell; 2010. Available from: <http://ezproxy.lib.le.ac.uk/login?url=http://www.myilibrary.com?id=269077>

78.

Gallwitz B, Rosenstock J, Rauch T, Bhattacharya S, Patel S, von Eynatten M, Dugi KA, Woerle HJ. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. *The Lancet*. 2012 Aug;380(9840):475–483.

79.

Rizos CV, Kei A, Elisaf MS. The current role of thiazolidinediones in diabetes management. *Archives of Toxicology*. 2016 Aug;90(8):1861–1881.

80.

Nissen SE, Wolski K. Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes. *New England Journal of Medicine*. 2007 Jun 14;356(24):2457–2471.

81.

Tanner M. Review: In type 2 diabetes, adding dipeptidyl peptidase-4 inhibitors to sulphonylureas increases hypoglycemia. *Annals of Internal Medicine*. 2016 Aug 16;165(4).

82.

Mishriky BM, Cummings DM, Tanenberg RJ. The efficacy and safety of DPP4 inhibitors compared to sulfonylureas as add-on therapy to metformin in patients with Type 2 diabetes: A systematic review and meta-analysis. *Diabetes Research and Clinical Practice*. 2015 Aug;109(2):378–388.

83.

Bennett WL, Maruthur NM, Singh S, Segal JB, Wilson LM, Chatterjee R, Marinopoulos SS, Puhan MA, Ranasinghe P, Block L, Nicholson WK, Hutfless S, Bass EB, Bolen S. Comparative Effectiveness and Safety of Medications for Type 2 Diabetes: An Update Including New Drugs and 2-Drug Combinations. *Annals of Internal Medicine*. 2011 May 3;154(9).

84.

Merlin C. Thomas. Systematic Literature Review of DPP-4 Inhibitors in Patients with Type 2 Diabetes Mellitus and Renal Impairment. *Diabetes Therapy [Internet]*. Springer; 2016;7(3). Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5014795/>

85.

Paul Craddy. Comparative Effectiveness of Dipeptidylpeptidase-4 Inhibitors in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison. *Diabetes Therapy [Internet]*. Springer; 2014;5(1). Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4065303/>

86.

Holt RIG, Cockram C, Flyvbjerg A, Goldstein BJ. *Textbook of Diabetes [Internet]*. 5th ed. Somerset: John Wiley & Sons, Incorporated; 2016. Available from: <http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056>

87.

Holt RIG. *Textbook of diabetes [Internet]*. 4th ed. Chichester: Wiley-Blackwell; 2010. Available from: <http://ezproxy.lib.le.ac.uk/login?url=http://www.myilibrary.com?id=269077>

88.

Ryder B, McKnight J, Blann A, Dhatariya K, Gregory R, Robinson T, Rowles S, Sharp P, Winocour PH, Walton C. ABCD position statement on GLP-1 based therapies and pancreatic damage. *Practical Diabetes*. 2013 Nov;30(9):388–391.

89.

Amori RE, Lau J, Pittas AG. Efficacy and Safety of Incretin Therapy in Type 2 Diabetes. *JAMA*. 2007 Jul 11;298(2).

90.

Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, Zychma M, Blonde L. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). *The Lancet*. 2009 Jul;374(9683):39–47.

91.

Type 2 diabetes: prevention in people at high risk | Guidance and guidelines | NICE. NICE; Available from: <http://www.nice.org.uk/guidance/PH38>

92.

Buse JB, Drucker DJ, Taylor KL, Kim T, Walsh B, Hu H, Wilhelm K, Trautmann M, Shen LZ, Porter LE. DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks. *Diabetes Care*. 2010 Jun 1;33(6):1255–1261.

93.

Buse JB, Bergenstal RM, Glass LC, Heilmann CR, Lewis MS, Kwan AYM, Hoogwerf BJ, Rosenstock J. Use of Twice-Daily Exenatide in Basal Insulin-Treated Patients With Type 2 Diabetes. *Annals of Internal Medicine*. 2011 Jan 18;154(2).

94.

Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. *The Lancet*. 2010 Jun;375(9733):2223–2233.

95.

Diamant M, Van Gaal L, Stranks S, Northrup J, Cao D, Taylor K, Trautmann M. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. *The Lancet*. 2010 Jun;375(9733):2234-2243.

96.

Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. *Diabetes, Obesity and Metabolism*. 2007 Mar;9(2):194-205.

97.

Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes | 1-Recommendations | Guidance and guidelines | NICE. NICE; Available from: <https://www.nice.org.uk/guidance/ta390/chapter/1-Recommendations>

98.

Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsbøll T. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. *New England Journal of Medicine*. 2016 Sep 15;

99.

Nauck MA, Meier JJ. The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions. *The Lancet Diabetes & Endocrinology*. 2016 Jun;4(6):525-536.

100.

Type 2 diabetes: lixisenatide | Evidence-review | Advice | NICE. NICE; Available from: <https://www.nice.org.uk/advice/esnm26/chapter/evidence-review>

101.

Dapagliflozin in combination therapy for treating type 2 diabetes June 2013 [Internet]. Available from: <http://www.nice.org.uk/guidance/ta288>

102.

Exenatide prolonged-release suspension for injection in combination with oral antidiabetic therapy for the treatment of type 2 diabetes | Guidance and guidelines TA 248 Feb 2015 [Internet]. Available from: <https://www.nice.org.uk/guidance/ta248>

103.

Liraglutide for the treatment of type 2 diabetes mellitus. TA203, Oct 2010 [Internet]. Available from: <https://www.nice.org.uk/guidance/ta203>

104.

Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. *New England Journal of Medicine*. 2016 Jul 28;375(4):311–322.

105.

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. *New England Journal of Medicine*. 2016 Nov 3;375(18):1797–1799.

106.

Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, Johansen OE, Woerle HJ, Broedl UC, Zinman B. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. *New England Journal of Medicine*. 2016 Jul 28;375(4):323–334.

107.

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. *New England Journal*

of Medicine. 2016 Nov 3;375(18):1799–1802.

108.

Courtney H, Nayar R, Rajeswaran C, Jandhyala R. Long-term management of type 2 diabetes with glucagon-like peptide-1 receptor agonists. *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy*. 2017 Mar;Volume 10:79–87.

109.

Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R, Kaufman KD, Koglin J, Korn S, Lachin JM, McGuire DK, Pencina MJ, Standl E, Stein PP, Suryawanshi S, Van de Werf F, Peterson ED, Holman RR. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. *New England Journal of Medicine*. 2015 Jul 16;373(3):232–242.

110.

Rotz ME, Ganetsky VS, Sen S, Thomas TF. Implications of incretin-based therapies on cardiovascular disease. *International Journal of Clinical Practice*. 2015 May;69(5):531–549.

111.

Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. *New England Journal of Medicine*. 2016 Jul 28;375(4):311–322.

112.

Levin PA, Nguyen H, Wittbrodt E, Kim SC. Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research. *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy*. 2017 Apr;Volume 10:123–139.

113.

Holt RIG, Cockram C, Flyvbjerg A, Goldstein BJ. *Textbook of Diabetes* [Internet]. 5th ed. Somerset: John Wiley & Sons, Incorporated; 2016. Available from: <http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056>

114.

Holt RIG. Textbook of diabetes [Internet]. 4th ed. Chichester: Wiley-Blackwell; 2010.
Available from: <http://ezproxy.lib.le.ac.uk/login?url=http://www.myilibrary.com?id=269077>

115.

Leff DR, Heath D. Surgery for obesity in adulthood. *BMJ*. 2009 Sep 22;339(sep22
1):b3402-b3402.

116.

Schauer PR, Kashyap SR, Wolski K, Brethauer SA, Kirwan JP, Pothier CE, Thomas S, Abood B, Nissen SE, Bhatt DL. Bariatric Surgery versus Intensive Medical Therapy in Obese Patients with Diabetes. *New England Journal of Medicine*. 2012 Apr 26;366(17):1567-1576.

117.

Riddle MC, Aronson R, Home P, Marre M, Niemoeller E, Miossec P, Ping L, Ye J, Rosenstock J. Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin: A 24-week, randomized, placebo-controlled comparison (GetGoal-L). *Diabetes Care*. 2013 Sep 1;36(9):2489-2496.

118.

Sjöström L, Lindroos AK, Peltonen M, Torgerson J, Bouchard C, Carlsson B, Dahlgren S, Larsson B, Narbro K, Sjöström CD, Sullivan M, Wedel H. Lifestyle, Diabetes, and Cardiovascular Risk Factors 10 Years after Bariatric Surgery. *New England Journal of Medicine*. 2004 Dec 23;351(26):2683-2693.

119.

Persaud SJ, Jones PM. A Wake-up Call for Type 2 Diabetes? *New England Journal of Medicine*. 2016 Sep 15;375(11):1090-1092.

120.

Fagin JA, Wells SA. Biologic and Clinical Perspectives on Thyroid Cancer. *New England Journal of Medicine*. 2016 Sep 15;375(11):1054–1067.

121.

National Obesity Observatory [Internet]. Available from: <http://www.noo.org.uk>

122.

Schauer PR, Bhatt DL, Kirwan JP, Wolski K, Aminian A, Brethauer SA, Navaneethan SD, Singh RP, Pothier CE, Nissen SE, Kashyap SR. Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 5-Year Outcomes. *New England Journal of Medicine*. 2017 Feb 16;376(7):641–651.

123.

Min SH, Yoon JH, Hahn S, Cho YM. Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta-analysis. *Diabetes/Metabolism Research and Reviews*. 2017 Jan;33(1).

124.

Dungan KM, Povedano ST, Forst T, González JGG, Atisso C, Sealls W, Fahrback JL. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. *The Lancet*. 2014 Oct;384(9951):1349–1357.

125.

Nauck M, Weinstock RS, Umpierrez GE, Guerci B, Skrivanek Z, Milicevic Z. Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5). *Diabetes Care*. 2014 Aug;37(8):2149–2158.

126.

Schauer PR, Bhatt DL, Kirwan JP, Wolski K, Aminian A, Brethauer SA, Navaneethan SD,

Singh RP, Pothier CE, Nissen SE, Kashyap SR. Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 5-Year Outcomes. *New England Journal of Medicine*. 2017 Feb 16;376(7):641–651.

127.

Bethel MA, Engel SS, Green JB, Huang Z, Josse RG, Kaufman KD, Standl E, Suryawanshi S, Van de Werf F, McGuire DK, Peterson ED, Holman RR. Assessing the Safety of Sitagliptin in Older Participants in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). *Diabetes Care*. 2017 Apr;40(4):494–501.

128.

Holt RIG, Cockram C, Flyvbjerg A, Goldstein BJ. *Textbook of Diabetes* [Internet]. 5th ed. Somerset: John Wiley & Sons, Incorporated; 2016. Available from: <http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056>

129.

Holt RIG. *Textbook of diabetes* [Internet]. 4th ed. Chichester: Wiley-Blackwell; 2010. Available from: <http://ezproxy.lib.le.ac.uk/login?url=http://www.mylibrary.com?id=269077>

130.

Bergenstal RM, Tamborlane WV, Ahmann A, Buse JB, Dailey G, Davis SN, Joyce C, Peoples T, Perkins BA, Welsh JB, Willi SM, Wood MA. Effectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes. *New England Journal of Medicine*. 2010 Jul 22;363(4):311–320.

131.

Choudhary P, Parrott NR, Birtles L, Rutter MK. Islet cell transplantation: current status in the UK (2012). *Practical Diabetes*. 2012 Sep;29(7):280–285.

132.

Pickup JC. Insulin-Pump Therapy for Type 1 Diabetes Mellitus. *New England Journal of Medicine*. 2012 Apr 26;366(17):1616–1624.

133.

Srinivasan P, Huang GC, Amiel SA, Heaton ND. Islet cell transplantation. *Postgraduate Medical Journal*. 2007 Apr 1;83(978):224-229.

134.

Liraglutide for the treatment of type 2 diabetes mellitus. TA203, Oct 2010 [Internet]. Available from: <https://www.nice.org.uk/guidance/ta203>

135.

Villani M, de Courten B, Zoungas S. Emergency treatment of hypoglycaemia: a guideline and evidence review. *Diabetic Medicine*. 2017 Sep;34(9):1205-1211.

136.

Dhatariya KK, Skedgel C, Fordham R. The cost of treating diabetic ketoacidosis in the UK: a national survey of hospital resource use. *Diabetic Medicine*. 2017 Oct;34(10):1361-1366.

137.

Leelarathna L, Roberts SA, Hindle A, Markakis K, Alam T, Chapman A, Morris J, Urwin A, Jinadev P, Rutter MK. Comparison of different insulin pump makes under routine care conditions in adults with Type 1 diabetes. *Diabetic Medicine*. 2017 Oct;34(10):1372-1379.

138.

Yates T, Davies MJ. Physical activity and Type 1 diabetes: an underused therapy. *Diabetic Medicine*. 2017 Nov;34(11):1498-1499.

139.

Narendran P, Jackson N, Daley A, Thompson D, Stokes K, Greenfield S, Charlton M, Curran M, Solomon TPJ, Nouwen A, Lee SI, Cooper AR, Mostazir M, Taylor RS, Kennedy A, Andrews

RC. Exercise to preserve β -cell function in recent-onset Type 1 diabetes mellitus (EXTOD) - a randomized controlled pilot trial. *Diabetic Medicine*. 2017 Nov;34(11):1521-1531.

140.

Holt RIG, Cockram C, Flyvbjerg A, Goldstein BJ. *Textbook of Diabetes* [Internet]. 5th ed. Somerset: John Wiley & Sons, Incorporated; 2016. Available from: <http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056>

141.

Holt RIG. *Textbook of diabetes* [Internet]. 4th ed. Chichester: Wiley-Blackwell; 2010. Available from: <http://ezproxy.lib.le.ac.uk/login?url=http://www.myilibrary.com?id=269077>

142.

Exercise and Glucose Metabolism in Persons with Diabetes Mellitus: Perspectives on the Role for Continuous Glucose Monitoring. *Journal of diabetes science and technology* (Online) [Internet]. 3(4). Available from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2769951/>

143.

Minimizing Hypoglycemia in Diabetes: Table 1. *Diabetes Care*. 2015 Aug;38(8):1583-1591.

144.

[ARCHIVED CONTENT] Medicines management: Everybody's business : Department of Health - Publications and statistics [Internet]. Available from: http://webarchive.nationalarchives.gov.uk/20080205132320/http://dh.gov.uk/en/publication/sandstatistics/publications/publicationspolicyandguidance/dh_082200

145.

Medicines adherence: involving patients in decisions about prescribed medicines and supporting adherence. CG76, Jan 2009 [Internet]. Available from: <https://www.nice.org.uk/guidance/cg76>

146.

Grammes J, Stock W, Mann CG, Flynn EM, Kubiak T. Focus group study to identify the central facets of fear of hypoglycaemia in people with Type 2 diabetes mellitus. *Diabetic Medicine*. 2017 Aug 30;

147.

Sivasubramaniyam S, Amiel SA, Choudhary P. Proportion of daily capillary blood glucose readings required in the target range for target glycaemic control: shift of focus from target range to proportion in range. *Diabetic Medicine*. 2017 Oct;34(10):1456-1460.

148.

Vloemans AF, van Beers CAJ, de Wit M, Cleijne W, Rondags SM, Geelhoed-Duijvestijn PH, Kramer MHH, Serné EH, Snoek FJ. Keeping safe. Continuous glucose monitoring (CGM) in persons with Type 1 diabetes and impaired awareness of hypoglycaemia: a qualitative study. *Diabetic Medicine*. 2017 Oct;34(10):1470-1476.

149.

Harman-Boehm I. Continuous glucose monitoring in type 2 diabetes. *Diabetes Research and Clinical Practice*. 2008 Dec;82:S118-S121.

150.

Bailey, Stephen. *Academic Writing: A Handbook for International Students* [Internet]. Available from: <http://lib.mylibrary.com.ezproxy4.lib.le.ac.uk/Open.aspx?id=310467>

151.

Creame P, Lea MR. *Writing At University: A Guide For Students* [Internet]. 3rd ed. Maidenhead: McGraw-Hill Education; 2008. Available from: <https://ebookcentral.proquest.com/lib/leicester/detail.action?pq-origsite=primo&docID=345134>